News | Atrial Fibrillation | January 31, 2020

Medtronic FDA Trial Evaluates Pulsed Electric Fields to Treat Atrial Fibrillation

Investigative new energy source technology designed to interrupt irregular pathways in the heart

Medtronic's PulseSelect Pulsed Field Ablation (PFA) System

Medtronic's PulseSelect Pulsed Field Ablation (PFA) System.


January 31, 2020 – The U.S. Food and Drug Administration (FDA) has given Medtronic approval to proceed with an investigational device exemption (IDE) trial to evaluate the safety and effectiveness of the PulseSelect Pulsed Field Ablation (PFA) System. This new technology that uses pulsed electric fields to treat atrial fibrillation (Afib or AF). 

The first procedures in the trial were recently performed. In December 2019 by Bradley Wilsmore, M.D., at John Hunter Hospital, New Lambton Heights, NSW, Australia, and in January by Atul Verma, M.D., the principal investigator (PI) for the study, at Southlake Regional Health Centre in Newmarket, Canada.

 

Pulsed Field Ablation Technology

PFA uses pulsed electric fields to ablate or create lesions and scar tissue to interrupt irregular electrical pathways in the heart and the triggers of atrial fibrillation. However, unlike traditional methods of ablation that heat the tissue (radio frequency) or cool the tissue (cryo) to ablate, PFA is non-thermal and selectively targets cardiomyocytes (heart muscle cells) while avoiding other types of tissue.

“This study will evaluate a new energy source that may treat atrial fibrillation and potentially address the risks that have been associated with other ablation technologies, such as unintended tissue damage,” Verma said. “The rigorous pre-clinical research to get us to these first procedures has been impressive and we are excited to support the development of more clinical evidence.”

In September 2018, Medtronic was granted breakthrough device designation from the FDA for the PFA technology for the treatment of drug refractory recurrent symptomatic atrial fibrillation. Worldwide, the PFA system is investigational and not approved for sale or distribution. 

The PULSED AF Trial 

PULSED AF study is a prospective, multi-center, non-randomized, unblinded and worldwide trial that will enroll patients who will be treated with the Medtronic PulseSelect PFA System.

“As a global leader in the treatment of cardiac arrhythmias, Medtronic is constantly evaluating new and existing therapies to better meet the needs of patients and the physicians who care for them,” said Rebecca Seidel, vice president and general manager in the AF solutions division, which is part of the Cardiac and Vascular Group at Medtronic. “The PULSED AF study is another example of our commitment to meaningful innovation and a major step forward in the development of a diverse set of therapy options for atrial fibrillation patients.”

For more information: www.medtronic.com

 

Related Pulse Electric Field Ablation Content:

First-in-human Electroporation Ablation Study Finds Pulsed Electric Fields Can Target Specific Tissue For Atrial Fibrillation

Boston Scientific Invests in Pulsed Field Ablation Technology To Improve Atrial Fibrillation Therapy

Pulsed AF Trial Shows Pulsed Field Ablation May be Safer Than Traditional RF Ablations

First Patients Treated with Galaxy Medical Centauri Pulsed Electric Field Cardiac Ablation System

Related Content

News | Ablation Systems

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter ...

Home April 05, 2021
Home
News | Ablation Systems

June 16, 2020 – The Montreal Heart Institute (MHI) and Thermedical, a developer of thermal-ablation systems to treat ...

Home June 16, 2020
Home
News | Ablation Systems

May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SERF) ...

Home May 08, 2020
Home
Feature | Ablation Systems

May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or ...

Home May 08, 2020
Home
Videos | Ablation Systems

Clifford Robinson, M.D., associate professor of radiation oncology, chief of the SBRT service, director of clinical ...

Home September 26, 2019
Home
News | Ablation Systems

September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically ...

Home September 17, 2019
Home
News | Ablation Systems

May 16, 2019 — Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter ...

Home May 16, 2019
Home
News | Ablation Systems

May 16, 2019 — CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the ...

Home May 16, 2019
Home
News | Ablation Systems

May 14, 2019 — The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an ...

Home May 14, 2019
Home
News | Ablation Systems

May 13, 2019 — Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands ...

Home May 13, 2019
Home
Subscribe Now